{"id":"W4380730064","doi":"10.1007/s13555-023-00942-y","title":"Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"LEO Pharma; Allergan; Argenx; Sanofi Genzyme; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Sanofi; Galderma; Ortho Dermatologics; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Eczema Area and Severity Index; Medicine; Discontinuation; Atopic dermatitis; Adverse effect; Dermatology Life Quality Index; Clinical endpoint; Internal medicine; Body surface area; Quality of life (healthcare); Clinical trial; Dermatology; Disease","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008540189,0.0002005604,0.0006414998,0.0002186408,0.0001221927,0.00001793619,0.0001245891,0.0001130916,0.00002507835],"category_scores_gemma":[0.00003247288,0.0001572143,0.00001714553,0.0003170174,0.0001555441,0.0001206175,0.0001010412,0.0001651403,0.00001234482],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001086818,"about_ca_system_score_gemma":0.00007202078,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002050894,"about_ca_topic_score_gemma":0.000027258,"domain_scores_codex":[0.9986924,0.0001895769,0.0003766249,0.0003351911,0.0001281336,0.0002780757],"domain_scores_gemma":[0.9993223,0.0001213841,0.00008227386,0.0002549294,0.00006743219,0.0001516787],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008674266,0.006628383,0.9679396,0.0001159603,0.0002171346,0.0006295712,0.001720006,0.000004157569,0.000007804247,0.0001213124,0.001033658,0.01290821],"study_design_scores_gemma":[0.07151181,0.0007948372,0.9255912,0.0001521361,0.00004818515,0.0002774801,0.0002914143,0.0001645876,0.0001227867,0.0001158246,0.000762085,0.0001676752],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958836,0.0009579795,0.00002034386,0.001181908,0.0000470618,0.001660479,0.0000233851,0.00004586238,0.0001793975],"genre_scores_gemma":[0.9976144,0.0005180443,0.00004253371,0.001643533,0.000006103207,0.00006320575,0.00005999145,0.00001877116,0.00003341127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06283755,"threshold_uncertainty_score":0.6411012,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02961108722512346,"score_gpt":0.3179160238496889,"score_spread":0.2883049366245655,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}